With less than four months to go until the launch of the new Unitary Patent and Unified Patent Court, one thing is for certain, the new system for centralised European patent litigation will have major implications for the UK’s highly innovative sectors – notably life sciences and biotech.
 
In a new article for the UK BioIndustry Association Community, PG’s Tim Powell and Jodie Goonawardena, in collaboration with Appleyard Lees IP LLP’s Kate Hickinson, offer guidance on what life sciences patent holders can expect from the new system and how they can best prepare over the coming months.
 
Read for free here.